Abstract
The treatment of metastatic, progressive thyroid cancer has evolved over recent years. New 'targeted' therapeutic approaches have been developed along with advances in the knowledge of thyroid carcinogenesis and the identification of tumor and endothelial targets. In recent years, results of targeted therapies have shown some benefit in refractory, progressive, differentiated, and medullary thyroid carcinomas but not, until recently, in undifferentiated thyroid carcinoma. We review here the different targeted therapies tested in thyroid cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
